Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis (VISIONARY-MS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03536559
Recruitment Status : Recruiting
First Posted : May 24, 2018
Last Update Posted : April 30, 2021
Sponsor:
Collaborator:
Clene Australia Pty Ltd
Information provided by (Responsible Party):
Clene Nanomedicine

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : September 2022